OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
GRBT58

Guerbet SA

Advanced Medical Equipment & TechnologyVerified

Guerbet's capital structure is characterized by a lack of dilution risk, as the number of basic and diluted shares outstanding is identical at 12.6 million shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. This lack of liquidity data limits the ability to evaluate the company's short-term financial flexibility. Profitability and return metrics are not available in the current valuation snapshot, which prevents a direct comparison with industry_config preferred metrics or cohort medians. Without access to key profitability indicators such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess Guerbet's performance relative to its peers in the Advanced Medical Equipment & Technology industry. Segment and geographic exposure data are not disclosed in the available financial snapshot, making it difficult to evaluate revenue concentration or geographic diversification. This lack of transparency limits the ability to assess potential risks from over-reliance on specific product lines or regions. Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or revenue history. Analysts have issued a mean price target of 11.60 EUR and a median of 12.00 EUR, with no strong buy or buy recommendations, and two hold ratings. This suggests a cautious outlook from the investment community. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The absence of balance-sheet data and going-concern language in source documents raises concerns about financial transparency. Dilution risk is currently low, but the lack of detailed capital structure data limits the ability to evaluate future dilution potential. Recent events and filings do not appear to be disclosed in the available data, which limits the ability to assess any material developments that may impact the company's operations or financial position. The absence of transcripts or recent filings suggests a lack of public disclosure activity.

30-day price · GRBT+0.19 (+1.9%)
Low$8.64High$12.66Close$9.99As of12 May, 00:00 UTC
Profile
CompanyGuerbet SA
TickerGRBT.PA
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryAdvanced Medical Equipment & Technology
AI analysis

Business. Guerbet SA is a French multinational company specializing in the development, production, and distribution of contrast media and radiopharmaceuticals for diagnostic imaging, primarily in the healthcare equipment and technology sector.

Classification. Guerbet is classified under the Healthcare sector, specifically in the Advanced Medical Equipment & Technology industry, with a high confidence level of 0.92 based on verified market data.

Guerbet's capital structure is characterized by a lack of dilution risk, as the number of basic and diluted shares outstanding is identical at 12.6 million shares. However, liquidity risk could not be assessed due to the absence of balance-sheet inputs and no going-concern language in source documents. This lack of liquidity data limits the ability to evaluate the company's short-term financial flexibility. Profitability and return metrics are not available in the current valuation snapshot, which prevents a direct comparison with industry_config preferred metrics or cohort medians. Without access to key profitability indicators such as ROIC, EBITDA margins, or net profit margins, it is not possible to assess Guerbet's performance relative to its peers in the Advanced Medical Equipment & Technology industry. Segment and geographic exposure data are not disclosed in the available financial snapshot, making it difficult to evaluate revenue concentration or geographic diversification. This lack of transparency limits the ability to assess potential risks from over-reliance on specific product lines or regions. Growth trajectory is also unclear, as the outlook section does not provide numeric deltas or revenue history. Analysts have issued a mean price target of 11.60 EUR and a median of 12.00 EUR, with no strong buy or buy recommendations, and two hold ratings. This suggests a cautious outlook from the investment community. Risk factors include the inability to assess liquidity risk, which could impact the company's ability to meet short-term obligations. The absence of balance-sheet data and going-concern language in source documents raises concerns about financial transparency. Dilution risk is currently low, but the lack of detailed capital structure data limits the ability to evaluate future dilution potential. Recent events and filings do not appear to be disclosed in the available data, which limits the ability to assess any material developments that may impact the company's operations or financial position. The absence of transcripts or recent filings suggests a lack of public disclosure activity.
Key takeaways
  • Guerbet's capital structure shows no dilution risk, with basic and diluted shares outstanding being equal.
  • Liquidity risk could not be assessed due to missing balance-sheet data and no going-concern language in source documents.
  • Profitability and return metrics are not available, preventing a comparison with industry benchmarks.
  • Analysts have issued a cautious outlook, with no strong buy or buy recommendations and two hold ratings.
  • Segment and geographic exposure data are not disclosed, limiting the ability to assess revenue concentration or diversification.
  • --
  • ## RATIONALES
  • ```json
Financial snapshot
PeriodHA-latest
CurrencyEUR
Revenue
Gross profit
Operating income
Net income
R&D
SG&A
D&A
SBC
Operating cash flow
CapEx
Free cash flow
Total assets
Total liabilities
Total equity
Cash & equivalents
Long-term debt
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY-4$732.1M$38.7M$32.6M$30.8M
FY-3$753.3M-$18.2M-$41.1M$4.9M
FY-2$785.7M$38.7M$23.9M$20.3M
FY-1$841.1M$49.6M$16.1M$12.5M
FY0$786.4M-$88.2M-$108.3M-$60.6M
PeriodGross %Op %Net %FCF %
FY-4
FY-3
FY-2
FY-1
FY0
PeriodAssetsEquityCashDebt
FY-4$1.00B$405.1M$115.7M
FY-3$939.6M$379.6M$41.7M
FY-2$1.03B$378.3M$51.3M
FY-1$1.04B$394.2M$50.2M
FY0$930.0M$267.0M$115.5M
PeriodOCFCapExFCFSBC
FY-4$116.0M-$48.9M$30.8M
FY-3$30.4M-$50.5M$4.9M
FY-2$27.4M-$56.7M$20.3M
FY-1$81.2M-$57.0M$12.5M
FY0$81.1M-$36.6M-$60.6M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ-7
FQ-6$201.3M
FQ-5
FQ-4$178.2M
FQ-3
FQ-2$198.7M
FQ-1
FQ0$175.8M
PeriodGross %Op %Net %FCF %
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodAssetsEquityCashDebt
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
PeriodOCFCapExFCFSBC
FQ-7
FQ-6
FQ-5
FQ-4
FQ-3
FQ-2
FQ-1
FQ0
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book
Net cash
Current ratio
Debt/Equity
ROA
ROE
Cash conversion
CapEx/Revenue
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskUnknown
  • Liquidity risk could not be assessed (no balance-sheet inputs and no going-concern language in source documents).
Industry benchmarks
Activity: Healthcare Equipment · cohort 91 companies
MetricGRBTActivity
Op margin-16.5% medp25 -174.5% · p75 8.8%
Net margin-16.5% medp25 -172.4% · p75 8.4%
Gross margin47.4% medp25 34.2% · p75 65.3%
CapEx / revenue-5.4% medp25 -12.5% · p75 -2.2%
Debt / equity4.3% medp25 0.0% · p75 28.0%
Observations
IR observations
Mean price target11.60 EUR
Median price target12.00 EUR
High price target13.80 EUR
Low price target9.00 EUR
Mean recommendation3.33 (1=strong buy, 5=strong sell)
Strong-buy count0.00
Buy count0.00
Hold count2.00
Sell count1.00
Strong-sell count0.00
Mean EPS estimate0.26 EUR
Last actual EPS-2.11 EUR
Source data
Underlying data the analysis-pipeline pulls and audits. Fetch timestamps + content hashes show when each source was last refreshed.
Company fundamentalsperiod FQ-7 · history via verified-market-data
no public URL
2026-05-12 02:01 UTC#370d3345
Source: analysis-pipeline (hybrid)Generated: 2026-05-28 01:37 UTCJob: 44a90c75